We need more educational or clinical projects that have a real-world impact on reducing disparities in dermatology, said Art Papier, MD, dermatologist, CEO, VisualDx.
Art Papier, MD, dermatologist, CEO, VisualDx, talks about disparity prevention in dermatology, including the second year of Project IMPACT, and considerations in artificial intelligence (AI) and machine learning.
Transcript
What are your goals for the second year of Project IMPACT?
I think we really want to see specific projects that are either educational or clinical that have real-world impact. Project IMPACT, the name, we chose that really because we want to be substantial. We don't want to just be performative and be just discussing an issue. We want to see some results. In the second year, we want to see more people involved and we want to see specific projects, and we're hoping to do specific projects around medical education.
How can we ensure future projects are including underserved populations in their research?
I think there's tremendous interest in primary care. So, in rural areas or inner city areas where you have federally qualified health clinics serving the underserved, there's a real need to bring the kind of information that those health care professionals can use in real time. In my work, I've been thinking about this problem, "What's the right information for the right patient population?" So we're thinking about, if the clinic is urban, what do they need? If the clinic's rural, what's the patient population? How do we really bring customized information to each population?
Since dermatological conditions can appear differently depending on skin type, what steps should be taken in AI development?
People are beginning to understand that AI and machine learning are totally dependent on good quality data. It's garbage in, garbage out. You have to have good data, and if you train your algorithms just on white skin, it's not going to work on brown skin.
So in our work at VisualDx, as an example, we've been collecting imagery for over 20 years, and since the start of our efforts, it's always been equitable. We have something like 32% of the imagery in the system is in brown skin, and we have tags on that imagery so that when we train our AI, it's equitable. This is key to having equity in AI and machine learning—it's the data you train on and how precise the data is.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More